42.71USD+3.84%Mkt Cap: 1.93B USDP/E: —Last update: 2026-05-26
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-dire…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.93B USD
Enterprise Value1.68B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.27M USD
Revenue/Share—
Last Price42.71 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.90
PEG—
EV/EBITDA-17.07
EV/Revenue—
P/S—
P/B6.53
EPS (TTM)-1.86
EPS (Forward)-2.80
52W Range
12.4284% of range48.45
52W High48.45 USD
52W Low12.42 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-24.53%
ROA-23.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-66.30M USD
CapEx (TTM)377.00K USD
FCF Margin—
FCF Yield-2.37%
Net Debt-207.77M USD
Net Debt/EBITDA2.11
Balance Sheet
Debt/Equity0.03
Current Ratio22.60
Quick Ratio22.11
Book Value/Sh6.394 USD
Cash/Share4.787 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)51.60 USD
Target Range23.00 USD – 63.00 USD
# Analysts10
Ownership
Shares Out.45.15M
Float16.50M
Insiders6.85%
Institutions100.59%
Short Interest
Short Ratio9.3d
Short % Float15.22%
Short % Out.9.37%
Shares Short4.23M
Short (prev mo.)3.76M
Technical
SMA 5039.65 (+7.7%)
SMA 20035.71 (+19.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)433.90K
Avg Vol (10d)403.06K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—